Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Armata Pharmaceuticals Inc (ARMP)

Armata Pharmaceuticals Inc (ARMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023 PR Newswire - Thu Oct 19, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a clinical stage biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference PR Newswire - Thu Sep 21, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update PR Newswire - Mon Aug 14, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update PR Newswire - Thu May 11, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update PR Newswire - Thu Mar 16, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC PR Newswire - Tue Jan 10, 2023

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
INVA : 19.80 (+1.59%)
Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection PR Newswire - Thu Dec 22, 2022

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update PR Newswire - Wed Nov 9, 2022

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update PR Newswire - Thu Aug 11, 2022

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific...

ARMP : 2.37 (+0.85%)
Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals PR Newswire - Thu Oct 28, 2021

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata," "us," "our," or the "Company"), a biotechnology company focused on...

ARMP : 2.37 (+0.85%)

Barchart Exclusives

Domino's Pizza Expands Its Free Cash Flow Margins - DPZ Stock is Worth 25% More Barchart - 15 minutes ago
Domino's Pizza reported strong Q3 revenue growth and expanded free cash flow margins, albeit with lower revenue guidance. As a result, DPZ stock is worth at least 25% more. Out-of-the-money put options are a good play. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot